The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Boehringer Ingelheim acquires all ViraTherapeutics shares to develop next-gen viral-based therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Boehringer Ingelheim has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies.

ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus with modified glycoprotein), which is being investigated alone and in combination with other therapies. The total transaction value of EUR 210 million is based on an option and share purchase agreement signed between the companies in Aug. 2016.

The lead investigational candidate leveraging the platform, VSV-GP, has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles Boehringer Ingelheim is developing.

ViraTherapeutics was a portfolio company of the two venture investors EMBL Ventures and the Boehringer Ingelheim Venture Fund (BIVF).

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
By W. Kimryn Rathmell

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account